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A B S T R A C T
Sonodynamic therapy (SDT) is a form of ultrasound therapy that has been shown to preferentially damage
malignant cells based on the relatively enlarged size and altered cytology of neoplastic cells in compar-
ison to normal cells. This study sought to determine whether cytoskeletal-directed agents that either
disrupt (cytochalasin B and vincristine) or rigidify (jasplakinolide and paclitaxel) microﬁlaments and mi-
crotubules, respectively, affect ultrasonic sensitivity. U937 human monocytic leukemia cell populations
were treated with each cytoskeletal-directed agent alone, and then sonicated at 23.5 kHz under rela-
tively low power and intensity (20–40W; 10–20W/cm2), or at 20 kHz using moderate power and intensity
(60W; 80W/cm2). In addition, human leukemia lines U937, THP1, K562, and Molt-4, and the murine leu-
kemia line L1210 were sonicated using pulsed 20 kHz ultrasound (80.6 W; 107.5 W/cm2) both with and
without the addition of cytoskeletal-directed agents to assess whether cytoskeletal-directed agents can
potentiate ultrasonic sensitivity in different leukemia lines. Human hematopoietic stem cells (hHSCs) and
leukocytes were sonicated with continuous 23.5 kHz ultrasound (20W; 10W/cm2) to determine whether
this approach elicited the preferential damage of neoplastic cells over normal blood components. To de-
terminewhether ultrasonic sensitivity is exclusively dependent on cell size, leukemia cells were also enlarged
via alteration of cell growth parameters including serum deprivation and re-addition, and plateau-
phase subculturing. Results indicated that cytochalasin B/ultrasound treatments had the highest rates
of initial U937 cell damage. The cells enlarged and partially synchronized, either by serum deprivation
and re-addition or by plateau-phase subculturing and synchronous release, were not comparably sen-
sitive to ultrasonic destruction based solely on their cell size. In addition, cytochalasin B signiﬁcantly
potentiated the ultrasonic sensitivity of all neoplastic cell lines, but not in normal blood cells, suggest-
ing that preferential damage is attainable with this treatment protocol. Therefore, it is likely that ultrasonic
cell lysis depends not only on cell size and type, but also on the speciﬁc molecular mechanisms used to
induce cell enlargement and their effects on cell integrity. This is supported by the fact that either the
microﬁlament-or microtubule-disrupting agent produced a higher rate of lysis for cells of a given size
than the corresponding stabilizing agents.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Sonodynamic therapy (SDT) is a form of ultrasound therapy in
which specialized chemotherapeutic agents known as sonosensitizers
are administered to increase the ability of ultrasound to preferen-
tial damage neoplastic cells [1–3]. It has been shown in numerous
experiments that ultrasound preferentially damages malignant cells
based on the size differential between such cells and those of normal
histology [4–7]. Therefore, SDT provides a novel physiochemical ap-
proach to cancer therapy. Indeed, SDT has been shown to have both
in vitro and in vivo eﬃcacy with a variety of cell lines [7–10], and
might eventually be used to supplement current chemotherapeu-
tic protocols. SDT has also shown particular eﬃcacy against drug
resistant cell lines. Ultrasound combined with doxorubicin (DOX)
signiﬁcantly increased its eﬃcacy on the human leukemiamultidrug
resistant cell line K562/A02, indicating that sonication can signiﬁ-
cantly increase DOX concentration within malignant cells to amplify
the cytotoxicity of DOX [8]. Such observations were exhibited in a
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cell line shown to be resistant to DOX-alone, further substantiat-
ing the amplifying effect sonosensitizers have in SDT. Evidence of
DOX-resistance reversal has also been shown in vivo, as athymic nude
mice inoculated with HepG2multidrug resistant hepatocellular car-
cinoma cells had an average 62% reduction in tumor volume amonth
later in ultrasound/DOX groups compared to DOX-only groups [11].
This ultrasound/DOX group signiﬁcantly down-regulated the ex-
pression of multidrug resistance protein-1 (MDR1) and multidrug
resistance-associated protein (MRP) at the mRNA level, while pro-
ducing excess reactive oxygen species (ROS) levels. This substantial
reduction of MDR1 and MRP indicates a reversal of drug resis-
tance, and provides evidence of the potential clinical utility of SDT.
In addition to its ability to reverse drug resistance, SDT is also able
to preferentially lyse cells based on size. This observation suggests the
possible therapeutic beneﬁt of enlarging neoplastic cells to further in-
crease their size difference compared to normal cells. Cell enlarging
agents act during mitotic events, such as the formation of the spindle
ﬁber and chromosome separation (microtubule-directed agents), or
during cytokinesis (microﬁlament-directed agents). Agents that act
duringmitotic events in leukemia are likely to affect the poorly differ-
entiated blasts that are responsible for observed pathological features,
leukemic stem cells (LSCs) that perpetuate leukemic blast formation,
and hematopoietic stem cells (HSCs) which give rise to normal blood
cell lineages. However, intravenous administration of vincristine typ-
ically acts preferentially toward leukemia cells in circulation, and it is
likely that other cell enlarging agents have a similar aﬃnity for neo-
plastic cells. Indeed, cytochalasin B has been shown to induce
enlargement and multinucleation in neoplastic cells while driving
normal cells out of the cell cycle rendering them small and mono-
nucleated [10,12]. Although normal HSCs are damaged by high dose
chemotherapy, the cell population can sometimes be rescued through
autologous stem cell rescue (ASCR), or donor bone marrow trans-
plants [13,14]. Moreover, since normal cells remain small and
mononucleated, it is likely that cell enlarging agents can be used con-
currently with ultrasound in a physicochemical approach to
preferentially damage leukemia cells,while producingminimal damage
to smaller normal cells.
Microtubule-directed agents have long been used in chemo-
therapy, and are a component of many current treatment protocols
for hematological malignancies, such as vinblastine in ABVD
(adriamycin/doxorubicin, bleomycin, vinblastine, and dacarbazine)
for the treatment of Hodgkin’s Lymphoma, and vincristine in acute
lymphoid leukemia (ALL) [15,16]. By contrast, there has yet to be
a microﬁlament-directed agent approved for clinical use. The con-
comitant use of both classes of cytoskeletal-directed agents appears
to be a viable chemotherapeutic approach. It is well known that ma-
lignant cells have a perturbed cytoskeleton which produces or is a
cause of dysplasia and subsequent anaplasia [17]. These cytoskeletal
alterations in neoplastic cells provide an ideal opportunity to obtain
preferential enlargement and enhanced ultrasonic damage. Since
microﬁlament-directed agents are cytokinesis inhibitors, it seems
likely that using such agents in combination with known
microtubule-directed mitotic inhibitors could elicit a synergistic or
at least additive effect. In theory, this combination would limit the
opportunity for malignant cells to carry out a successful mitosis as
the microtubule-directed agents would prevent proper formation
of a spindle ﬁber, while any cells that managed to evade this
microtubule-directed mechanism and replicate their nuclei would
be unable to undergo cytokinesis in the absence of functioning mi-
croﬁlaments. This weakened cytoskeleton can be further exploited
when a physical modality such as ultrasound is used concurrently
with cytoskeletal-directed agents, especially because neoplastic cells
are fundamentally more susceptible to damage by ultrasound
[1,2,18–20].
We have previously demonstrated that leukemia cells are pro-
foundly sensitive to cytochalasin B in conjunction with ultrasound
[10]. Therefore, this study seeks to determine whether microtubule-
directed agents elicit the same response. Since vincristine is
commonly used in the treatment of hematological malignancies, it
is an ideal microtubule-directed agent to compare with cytocha-
lasin B. In addition, microﬁlament-stabilizing jasplakinolide and
microtubule-stabilizing paclitaxel are also assessed to determine
whether the mechanism of cell enlargement (disruption vs.
rigidiﬁcation) has any bearing on ultrasonic sensitivity. However,
it may be the case that ultrasonic sensitivity is exclusively depen-
dent on cell size, with other cytotoxic effects potentiated by
chemotherapeutic agents having almost no inﬂuence on lysis rates.
We have previously demonstrated that untreated log-phase U937
monocytic leukemia cells ranging from 10 to 21 μm in diameter are
sensitive to sonication, and that U937 cells enlarged by treatment
with cytochalasin B show increased ultrasonic sensitivity because
the cells are enlarged compared to untreated U937 cells [10]. In order
to determine whether untreated leukemia cells of a given diame-
ter exhibit the same ultrasonic sensitivity as treated cells of the same
diameter, we examined leukemia cells enlarged via alteration of cell
growth parameters such as serum deprivation and re-addition, and
plateau-phase subculturing. These cells enlarged by alteration of cell
growth conditions rather than by treatment with cytoskeletal-
directed agents were then sonicated to determine whether their
sensitivity at a given diameter is comparable to that of cells en-
larged via treatment with chemotherapeutic agents. It is crucial to
determine whether cell size alone potentiates sensitivity to low fre-
quency ultrasound, or whether treatments affecting cytoskeletal
elements and/or membrane composition and ﬂuidity can enhance
or antagonize ultrasonic lysis of enlarged neoplastic cells.
Materials and methods
Cell preparation and size analysis
U937 human monocytic leukemia cells (ATCC® CRL-1593.2) were placed at
5.2 × 104 viable cells/ml in 20% fetal bovine serum (FBS) in Iscove’s mediumwithout
glutamine, with the following added: 200 units/ml penicillin, 200 μg/ml strepto-
mycin, 100 μg/ml gentamicin sulfate, 40 μM glutamine (50 μl of 2 mM glutamine
per 5 ml medium), and 50 μl of amphotericin B (2.5 μg/ml concentration) per 5 ml
of medium. K562, Molt-4, and THP1 human leukemia (ATCC® CCL-243, CRL-1582,
TIB-202), as well as L1210 murine leukemia (ATCC® CCL-219) were cultured under
the same conditions. Human hematopoietic stem cells (hHSCs) and human leuko-
cytes acquired from the State University of New York Upstate Medical University
(Syracuse, NY, USA) were also cultured under these conditions. Cells were stained
with Wright–Giemsa and DAPI (4′,6-diamidino-2-phenylindole) to examine nuclear
structure. A Z2 Beckman-Coulter® Particle Count and Size Analyzer (Beckman Coulter
Inc., Brea, CA, USA) along with a Bio-Rad® TC20 Automated Cell Counter (Bio-Rad
Laboratories, Inc., Hercules, CA, USA) were used for size determination. Cell viabil-
ity was determined with trypan blue staining and analysis with the TC20 cell counter.
Enlarging U937 cells by serum deprivation and re-addition
In order for U937 cells to be enlarged by serum deprivation and re-addition, the
cells were kept in serum-free or low serum (1%)medium to produce a very lowmitotic
fraction (cells at the G0 arrest phase). This required ﬁnding the optimal time for col-
lection of the cells after re-addition of 20% FBS to yield the maximum percentage
of enlarged cells. Cells were kept in serum-free conditions for 12, 22, 26 or 46 hours
before 20% FBS was returned to the growth medium. Cell counts were then taken
at various intervals to determine the optimal time of U937 cell population enlarge-
ment. Both plateau-phase and log-phase cells were treated under the same conditions
to determine if initial mitotic stage had any inﬂuence on cell size.
Enlarging U937 cells through plateau-phase subculturing
Plateau-phase subculturing involves growing cells to very late conﬂuent plateau-
phasewhere themitotic fraction is less than 4%; then achieving partial synchronization
by subculturing the cells back to early log-phase, referred to as subculture release.
Plateau-phase cells at 1.2 × 106 U937 cells/ml (about 4% mitosis) were subcultured
to 1 × 105 total cells/ml. The full spectrum of cell sizes from 13 to 32 μm was de-
termined at 0, 6, 12, 18, 24, 30, 31, 36, 46 and 52 hours after subculture to determine
the optimal time for obtaining the highest possible percentage of enlarged cells
≥19 μm.
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Enlarging leukemia cells using cytoskeletal-directed agents
Concentrations for each cytoskeletal-directed agent were chosen based on the
50% inhibitory concentration (IC50) assessed by MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) assay or by cell counts with the TC20 automated
cell counter using trypan blue to assess viability. Cells exposed to microtubule-
directed agents were treated with either 4 nM vincristine or 6 nM paclitaxel for 12
hours prior to sonication. Cells exposed tomicroﬁlament-directed agents were treated
with either 2 μM cytochalasin B or 0.5 μM jasplakinolide for 48 hours prior to soni-
cation. The different durations of exposure prior to sonication reﬂect the fact that
microtubule-directed agents exert their cell biological effects at lower doses andmore
rapidly than do the microﬁlament-directed agents.
Sonication of cell populations
U937 cells were put into 2.4 cm diameter glass vials with Mylar bottoms. The
cells were seeded in 1.0ml of 20% FBS mediumwith 1% Gibco® Fungizone (Life Tech-
nologies, Grand Island, NY, USA). Each vial contained 3ml of cells. Cells were sonicated
using a Fisher Scientiﬁc® Sonic Probe (23.5 kHz) system (Fisher Scientiﬁc Interna-
tional Inc., Hampton, NH, USA), or a Fisher Scientiﬁc® Sonic Horn (20 kHz, 7.5 cm
diameter cup) system (Fisher Scientiﬁc International Inc.). The target vial was moved
in a circular path within an orbital plane with a Bellco® Orbital Shaker (Fisher Sci-
entiﬁc International Inc.). Mylar-bottomed vials were sonicated in a 7.0 cm bath with
deionized, distilled, and degassed water. The target vial was located 6.0 cm from the
sonic horn. Cells were sonicated at 20–40W (10–20W/cm2) for the 23.5 kHz system
(2 mm diameter probe tip), or at 60W (80W/cm2) for the 20 kHz system. In addi-
tion, cells were sonicated using thirty 1 second pulses of 20 kHz ultrasound (80.6W;
107.5W/cm2) with 1 second spaced in between each pulse. Trypan blue staining was
used to identify non-viable cells after sonications were performed. U937 cell popu-
lations exposed to serum deprivation and re-addition, as well as plateau phase
subculturing were sonicated under the same conditions.
Cell cycle analysis and viability of leukemia cells
To conﬁrm that U937 cells were either in log- or plateau-phase, cell popula-
tions were analyzed with a XTT Cell Proliferation Assay Kit (ATCC® 30-1011K), which
measures whether cells are proliferating (log-phase) or conﬂuent (plateau-phase).
In addition, the XTT kit was used to assess the reduction in mitochondrial activity
and cell viability following treatment of cytoskeletal-directed agents and/or ultra-
sound against the leukemia lines.
Results
Effects of varying cell growth parameters on cell size: serum
deprivation and re-addition
Deliberately withholding serum from U937 cells to induce G0
arrest before reintroduction of 20% FBS appeared to be a reliable
method to enlarge cell populations. The optimal time to collect U937
cells was 6–12 hours after serum re-addition. This timing pro-
duced the highest proportion of large cells (17–20% ≥ 19 μm)
compared to later times in the cell cycle after serum re-addition
(Fig. 1A). This was after the log-phase cell population had been de-
prived of serum for 22 hours, and shows that cells synchronized
in the G0 arrest phase can be substantially enlarged through re-
addition of 20% FBS at an optimal time. In addition, trypan blue
staining indicated that cell populations maintained high viability
after 24 hours in low serum, suggesting that this method is not sig-
niﬁcantly deleterious to U937 cells. The same method was then
applied to mid-log and plateau-phase cells in order to determine
whether initial cell cycle status had any bearing on cell enlarge-
ment. Results revealed that both cell populations were enlarged to
the same extent, in the range of 17–20% (Fig. 1B), indicating that
initial cell cycle status had minimal inﬂuence on enlarging U937
cell populations.
Effects of varying cell growth parameters on cell size: plateau-phase
subculturing
Similar effects of cell enlargement were seen in plateau-phase
subculturing 35 hours after conﬂuent plateau-phase cells were sub-
cultured back into early log-phase (Fig. 1C), as 19% of the cells were
≥19 μm. In addition, cell cycle analysis using the XTT kit indicated
that log-phase cells readily reduced XTT to a soluble, brightly colored
orange derivative by mitochondrial reduction, while the activity of
XTT reduction in plateau-phase cells leveled off (Fig. 1D).
This conﬁrmed that log-phase cells were indeed proliferating,
while plateau-phase cells had become conﬂuent and quiescent.
Effects of cytoskeletal-directed agents on cell size
Microtubule-directed agents were able to substantially in-
crease the average cell size of U937 cells, as both 4 nM vincristine-
treated and 6 nM paclitaxel-treated cells exhibited a 50% increase
in cell size in comparison to untreated log-phase cells (Fig. 2A).
Similar results were obtained with microﬁlament-directed agents
when compared to serum deprivation and re-addition treated cells
(Fig. 2B). The generation of cells ≥24 μm was apparent with 2 μM
cytochalasin B after 2 days of treatment. Jasplakinolide at 0.5 μM
for 2 days produced cell enlargement comparable to serum-
synchronized cells. Visualization of cells enlarged by either
cytochalasin B (microﬁlament-disrupting agent) or vincristine
(microtubule-disrupting agent) is provided in Fig. 3, with
multinucleation only being present in cells enlarged by cytochala-
sin B.We have previously characterized the extent of multinucleation
in U937 cell populations treated with concentrations ranging from
0 to 4 μM cytochalasin B over a course of 8 days [21]. The present
study involved treating U937 cells with 2 μM cytochalasin B for 48
hours, and a similar extent of multinucleation was characterized
with these populations as in Ref. 21 (58% with 1 nucleus, 15% with
2 nuclei, 7% with 3 nuclei, 15% with 4 nuclei, and 5% with >4 nuclei).
Comparison of ultrasonic sensitivity potentiated by serum
deprivation and re-addition, by microﬁlament-directed, or by
microtubule-directed agents
As expected, U937 cells enlarged by serum deprivation and re-
addition exhibitedmarked increases in % damage to larger cells after
ultrasonic treatment. Cell populations enlarged by serum depriva-
tion and re-addition had noticeable sensitivity to ultrasound, as the
50% inhibitory concentration (IC50) value for cells ≥19 μmwas reached
by 8min using 20W (10W/cm2), 23.5 kHz ultrasound (Fig. 4A). Cells
enlarged by plateau-phase subculturing demonstrated ultrasonic sen-
sitivity comparable to those exposed to serum deprivation and re-
addition (data not shown). Although cells enlarged by serum
deprivation and re-addition demonstrate marked ultrasonic sen-
sitivity, 4 nM vincristine-treated cells ≥19 μm were even more
ultrasonic sensitive. Vincristine-treated cells >17 μm or >19 μm
reached IC50 values by 4.2 or 3.8 min, respectively under the same
conditions as employed in Fig. 5 (Fig. 4B). Interestingly, although 4 nM
vincristine and 6 nM paclitaxel-treated U937 cells exhibited a similar
increase in average cell size (Fig. 2A), paclitaxel cells ≥19 μm ap-
peared to be more resistant to sonication, as it took ~6 min for an
IC50 value to be reached using 40 W (20 W/cm2), 23.5 kHz ultra-
sound (twice the intensity as used in Figs. 4A and B). This indicates
that it took microtubule-stabilized (paclitaxel) cells ~2 min longer
to reach an IC50 value than microtubule-disrupted (vincristine) cells,
even though the paclitaxel-treated cells received higher power (20W
higher power) and intensity (10 W/cm2 higher intensity) ultra-
sound at 23.5 kHz.
When microﬁlament-directed agents were compared, the dif-
ference between disrupting and stabilizing agents became more
apparent. 2.0 μM cytochalasin B-treated cells ≥19 μm reached an IC50
value at ~1.7 min at 23.5 kHz, 20W(10W/cm2), and the same size
population was reduced to ~18% of the original cell population after
only 1 min of sonication at 20 kHz, 60W (80W/cm2) (Fig. 4D). By
contrast, jasplakinolide-treated cells did not reach an IC50 value until
well-after 4 min sonication (Fig. 4D). This is particularly telling,
as cytochalasin B-treated cells were much more sensitive to
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ultrasound, even when low power, moderate intensity (20W, 10W/
cm2) ultrasound/cytochalasin B-treated cells were compared to
moderate power and intensity (60 W, 80 W/cm2) ultrasound/
jasplakinolide-treated cells.
It also appeared that cytochalasin B-treated cells were more sen-
sitive to sonication than vincristine-treated cells or to cells enlarged
by serum deprivation and re-addition (Fig. 5A), as all of these groups
were sonicated under comparable conditions using 23.5 kHz, 20W
(10W/cm2) ultrasound. Similar results for all treated cell groupswere
attainedwith 20 kHz, 60W (80W/cm2) ultrasound, with cytoskeletal-
disrupting agents potentiating more ultrasonic damage than
cytoskeletal-stabilizing agents (Fig. 5B). It is interesting to note that
although microﬁlament-stabilizing jasplakinolide appeared more
toxic than microﬁlament-disrupting cytochalasin B, and required
a lower concentration to treat the cells prior to sonication, it con-
ferred the least ultrasonic sensitivity in comparison to the other
treatment groups.
Effects of cytoskeletal-disrupting agents on multiple leukemia lines
and normal human blood cells
The combination of cytoskeletal-disrupting agents and thirty 1
second pulses of 20 kHz ultrasound (80.6 W; 107.5 W/cm2) spaced
1 second apart appeared to decrease the viability of multiple leu-
kemia lines (human lines: U937, THP1, K562, and Molt-4; murine
line: L1210) more than ultrasound-alone or the administration of
A B
C D
Fig. 1. Effects of serum deprivation and re-addition and subculture release on U937 cells. A) Inﬂuence of serum deprivation and re-addition on U937 cell size. Negative
time reﬂects duration of serum deprivation. Left y axis (red) reﬂects the concentration of cells ≥13 μm, while the right y axis (black) shows the percentage of cells that are
≥19 μm and larger relative to the total population of cells ≥ 13 μm. Trypan blue staining revealed that U937 cell populations retain their viability (93% to 99%) at all points
during the experiment. 91% of U937 cells were ≥ 13 μm at time 0, (22 hours of serum deprivation), while 9% were 8–12 μm. 20% of the cells ≥ 13 μm were ≥ 19 μm 6 hours
after serum re-addition. B) Comparison of plateau- and log-phase U937 cell size after serum deprivation and re-addition. ≥ 8 μm (black); ≥ 13 μm (blue); ≥ 19 μm (red). A)
Plateau-phase cells are shown in the left-hand panel and log-phase cells in the right-hand panel. The left y axis shows the average volume of the cells, while the right y
axis corresponds to % of cells that are ≥ 19 μm from a total population that is ≥ 13 μm. After 46 hours serum deprivation, cells in plateau phase before serum re-addition
had 4% of cells ≥ 19 μm. 10 hours after serum re-addition, 20% of cells were ≥ 19 μm. Log-phase cells that had 8% of the cells ≥ 19 μm initially, reached 17% ≥ 19 μm 10 hours
after serum re-addition. C) Percentage of U937 cells ≥ 19 μm following subculture release. Cells were subcultured back into early log-phase at 0 hours. D) XTT proliferation
assay of U937 cells in log- or plateau-phase. 100 μl cells were seeded per well into a ﬂat-bottom 96-well microtiter plate in triplicate for each cell dilution. The plate was
incubated for 24 hours prior to addition of XTT solution. Cells were then incubated for an additional 2 hours before the wavelength was read. X axis refers to the cell number
in units of 103. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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cytochalasin B or vincristine (Fig. 6A). Further, both U937 and THP1
cells had a much higher reduction in cell viability as assessed by
XTT reduction when either cytochalasin B or vincristine was com-
bined with ultrasound, with cytochalasin B-treated cells again
demonstrating more ultrasonic sensitivity (Fig. 6B). The effects of
cytochalasin B and 23.5 kHz, 20 W (10W/cm2) continuous ultra-
sound on normal human blood cells are particularly intriguing, as
hHSCs and human leukocytes are damaged markedly less by the
treatment in comparison to U937 cells, even after 2 μM cytocha-
lasin B was added for 48 hours prior to sonication (Fig. 6C). The
potential importance of these ﬁndings will be elaborated upon in
the discussion.
Discussion
As assessed by cell enlarging agents and by varying growth con-
ditions to obtain enlarged cells, SDT preferentially damages U937
cells based on size. Cells ≥19 μm as a consequence of serum dep-
rivation and re-addition, or because of chemotherapeutically-
induced enlargement were damaged far more than cells ≥13 μm.
Since cytochalasin B- and vincristine-treated cells were more sen-
sitive to ultrasound than cells of the same size produced by
cytoskeletal-stabilizing agents (jasplakinolide and paclitaxel), or by
exposure to serum-deprivation or plateau-phase subculturing, it
is apparent that the method used to obtain enlarged cells has
Fig. 2. Size distribution of log-phase U937 cells treated with cytoskeletal directed agents. A) Cells treated with microtubule-directed agents. Cells were either treated with
4 nM vincristine (VCR), or 6 nM paclitaxel (Tax) for 12 hours. The left y axis corresponds to the % total of cells ≥13 μm that attained the cell size given on the x axis, while
the right y axis corresponds to the average cell volume of cells ≥13 μm after being treated with the indicated agent. B) Cells treated with microﬁlament-directed agents or
serum deprivation and re-addition. Cells were treated with either 2 μM cytochalasin B (CB) or 0.5 μM jasplakinolide (Jas) for 48 hours.
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a substantial inﬂuence on subsequent damage by sonication. It was
interesting to note that cytochalasin B-induced microﬁlament dis-
ruption potentiated higher sensitivity than did vincristine-induced
microtubule-disruption, suggesting that microﬁlaments may be a
more important target in SDT than microtubule-directed agents. It
is reasonable to propose that cytochalasin B or other microﬁlament-
disrupting agents can be combined with microtubule-disrupting
agents (vincristine and other vinca alkaloids) to enhance SDT, rather
than combining cytochalasin B with agents that rigidify microtu-
bule polymers (paclitaxel and docetaxel/taxotere). Combined
cytoskeletal-directed chemotherapy prior to sonication is indeed a
sensible prospect, and will be the subject of a future study.
The administration of cytochalasin B or vincristine prior to soni-
cation appears to potentiate the ultrasonic sensitivity of leukemia
lines U937, THP1, K562, Molt-4, and L1210 (Fig. 6A). Further, the
extent of damage potentiated by these cytoskeletal-disrupting agents
and ultrasound is much greater than either ultrasound-alone, or the
administration of cytochalasin B or vincristine. These data indi-
cate that cytoskeletal-disrupting agents are potent sonic sensitizing
agents in multiple types of leukemia, including acute myeloid leu-
kemia (U937 and THP1), chronic myeloid leukemia (K562), acute
lymphoid leukemia (Molt-4), and murine lymphoid leukemia
(L1210). In each cell line, cytochalasin B potentiated ultrasonic sen-
sitivity much more than vincristine, indicating that microﬁlament-
disrupting agents are likely more potent sonosensitizers than
microtubule-disrupting agents. Further, the ability of both U937 and
THP1 leukemia to reduce XTT is substantially decreased following
sonication with 20 kHz pulsed ultrasound (Fig. 6B). This is indica-
tive of a marked decrease in mitochondrial activity and cell viability,
hallmarks of apoptosis. While XTT assays are unable to fully conﬁrm
that apoptosis is occurring, it is likely that this form of pro-
grammed cell death is present in sonicated cells. Apoptosis prevents
cells from reducing tetrazolium dyes, as mitochondrial activity is
degraded in the initial steps of this biological process. Therefore,
the data acquired by the present study, as well as multiple studies
that have conﬁrmed the presence of apoptosis in human leuke-
mia cells following sonication (including U937 and K562 [20,22–24]),
indicate that ultrasound can induce apoptosis in this type of cancer.
Interestingly, U937 cells are preferentially damaged by 23.5 kHz
ultrasound over hHSCs and human leukocytes, even after the ad-
ministration of 2 μM cytochalasin B for 48 hours (Fig. 6C). The extent
of preferential damage appears to be signiﬁcant, as cytochalasin
B-treated normal blood cells were damaged markedly less by ex-
posure to 23.5 kHz, 20W (10W/cm2) ultrasound for 4 min than
cytochalasin B-treated U937 cells. Therefore, the present study sug-
gests that leukemia cells are preferentially damaged over normal
blood cells in the presence of cytochalasin B and ultrasound. This
has potential in vivo implications, as it may be possible to directly
sonicate the blood of leukemia-challenged mammalian models to
reduce the load of leukemic blasts in the presence of normal blood
components through extracorporeal blood sonication [25]. In ad-
dition, it may be possible to use the penetrating power of ultrasound
to sonicate the bone marrow of patients to preferentially
damage leukemic stem cells in the presence of hHSCs, which are
often responsible for propagating the disease [25]. However,
these ﬁndings should be extended to leukemic stem cells,
erythrocytes and megakaryocytes/thrombocytes prior to in vivo
experimentation.
Fig. 3. Effects of cytochalasin B and vincristine on U937 cell size. A) Untreated U937 cells. B) U937 cells treated with 2 μM CB for 48 hours. C) U937 cells treated with 4 nM
VCR for 11 hours. Gray arrows indicate a mononucleated cell that was not enlarged by the treatment. Red arrows indicate a cell that was enlarged by the treatment. Nuclei
were visualized with Wright–Giesma stain. Photomicrographs for panels A and B were taken under identical conditions of magniﬁcation (100×). The photomicrograph for
panel C was taken at 400× to conclusively determine whether any multinucleation was present. (For interpretation of the references to color in this ﬁgure legend, the reader
is referred to the web version of this article.)
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It is well known from chemotherapeutic approaches used in the
clinic that monotherapies employing only a single drug are typi-
cally not effective, as primary or secondary levels of drug resistance
typically emerge within heterogeneous tumorigenic growths. While
the treatment may have valuable initial success, cells resistant to
the treatment often arise, and subsequently repopulate tumors with
drug resistant cells. Therefore, it is necessary to treat malignan-
cies with a variety of antineoplastic agents concurrently, as it is much
more diﬃcult for malignant cells to acquire simultaneous resis-
tance to combinations of chemotherapeutic agents that function by
diverse mechanisms [25]. That is why the concomitant use of cy-
tochalasin B and vincristine along with ultrasound appears to be
such a sensible prospect. Cytochalasin B-inducedmicroﬁlament dis-
ruption may synergize very well with vincristine-induced
microtubule disruption, reducing the ability of leukemia cells to pro-
liferate, and profoundly increasing the sensitivity of these cells to
ultrasound through cell enlargement. Indeed, experiments per-
formed by our laboratory assessing the reduction in clonogenicity
following concomitant administration of cytochalasin B/vincristine
support the synergistic potential of these agents (Fig. 7). Further,
we have demonstrated that cytochalasin B/ultrasound substantial-
ly decreases clonogenicity in U937 cells [10], and we have
Fig. 4. Effects of sonication on cells treated with cytoskeletal-directed agents or serum deprivation and re-addition. A) Sonication of U937 cells at 6 hours after 20% serum
re-addition to cells deprived of serum for 22 hours. Sonications were performed at 20W (10W/cm2), 23.5 kHz. The distribution of cell sizes before sonication is provided
on the graph. Bars reﬂect SEM of 3 independent populations of U937 cells. B) Sonication with 23.5 kHz probe of U937 cells at 20W (10W/cm2) treated with 4 nM vincris-
tine for 12 hours. The distribution of cell sizes after treatment is provided on the graph. The ultrasonic sensitivity of vincristine-treated cells ≥19 μm are compared to the
same size range of cells attained from serum deprivation and re-addition. Bars reﬂect SEM of 3 independent populations of U937 cells. C) Sonication with 23.5 kHz probe
of U937 cells at 40W (20W/cm2) treated with 6 nM paclitaxel for 12 hours. Bars reﬂect SEM of 4 independent populations of U937 cells. D) Comparison of cytochalasin B
and jasplakinolide for determining ultrasonic sensitivity of treated U937 cells. CB-treated cells were sonicated at 20 kHz, 60W (80W/cm2) or 23.5 kHz, 20W (10W/cm2).
Jas-treated cells were sonicated at 20 kHz, 60W (80W/cm2). Bars reﬂect SEM of 3 or 4 independent U937 cell populations for CB-treated cells, and 4 independent cell popu-
lations for Jas-treated cells.
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determined that cytochalasin B/vincristine/ultrasound greatly po-
tentiates this clonogenic reduction (Table 1). It is unlikely that the
enlarged cellular phenotype will be able to generate biochemically-
based resistance to an extrinsic physical agent that damages cell
integrity and cell clonogenicity by affecting overall cellular integ-
rity at the macroscopic level as opposed to affecting a deﬁned
intracellular signaling pathway. It is not unusual for a sub-population
of cancer cells to evade the effects of vincristine and complete
nuclear replication. However it is far less probable that the
same sub-population could generate resistance to cytochalasin
B and circumvent the effects of disrupted microﬁlaments on
cytokinesis. The leukemic cells treated with both classes of
Fig. 5. Comparison of ultrasonic sensitivity potentiated by different cytoskeletal-directed agents under the same sonication protocols. A) Comparison of ultrasonic sensi-
tivity potentiated by cytoskeletal-disrupting agents and serum deprivation and re-addition. All cells were sonicated with 23.5 kHz ultrasound at 20W (10W/cm2). Bars
reﬂect SEM of 4 independent U937 cell populations for cells enlarged by serum deprivation and re-addition, and 3 independent cell populations for CB- and VCR-treated
cells. B) Comparison of cell enlarging protocols to determine ultrasonic sensitivity using 20 kHz, 60W (80W/cm2) ultrasound. Abbreviations for the type of cytoskeletal-
directed agent are provided in the ﬁgure. All cell populations were sonicated for 1 min. Bars reﬂect SEM of 4 independent U937 cell populations for all treatment groups.
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cytoskeletal-disrupting agents would therefore be forced to become
enlarged and ultrasonic sensitive and would be unable to circum-
vent two cytoskeletal-directed agents that act by completely distinct
mechanisms.
Combining ultrasound with cytoskeletal-directed agents may
yield improved antineoplastic cell effects. Indeed, the synergistic po-
tential of cytochalasin B and vincristine without ultrasonic treatment
has already been well described [26]. When various malignant cell
types were exposed to cytochalasin B/vincristine treatments, the
resultant DNA fragmentationwas greater than the sum of that caused
by each agent alone, demonstrating a synergistic relationship. Further,
the study indicated that the levels necessary to achieve this poten-
tiation are obtainable in vivo, indicative of a potential therapeutic
prospect.
While there has been a substantial array of in vivo studies that
indicate the therapeutic potential of SDT [9,27–30], more studies
of this nature are needed before the novel approach can be at-
tempted in the clinical setting. If eventual clinical studies determine
Fig. 6. Effects of cytoskeletal-directed agents and ultrasound on multiple leukemia lines and normal human blood cells. A) Ultrasonic sensitivity of multiple leukemia lines
before and after treatment with 2 μM cytochalasin B and 4 nM vincristine. Non-Son (non-sonicated); Son (sonicated). B) Effects of ultrasound-alone and in combination
with 2 μM cytochalasin B or 4 nM vincristine on reducing mitochondrial activity and cell viability in U937 and THP1 lines. C) Effects of cytochalasin B and ultrasound on
normal human leukocytes and hematopoietic stem cells. Abbreviations used are as follows: hHSCs (human hematopoietic stem cells); hWBCs (human white blood cells,
leukocytes).
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that ultrasound combined with cytoskeletal-directed agents alone
is not effective, there are a large variety of other cancer chemo-
therapeutic agents not directed speciﬁcally toward the cytoskeleton.
These clinically-active chemotherapeutic agents in combination with
cytoskeletal-directed agents could potentiate sonic sensitivity by con-
tributing to cell enlargement and other forms of cell disruption,
including membrane alteration [10]. Further reﬁnements could be
made using other cytoskeletal-directed agents including agents af-
fecting the intermediate ﬁlaments, and by using agents affecting
cytosolic and membrane integrity and cell size to determine con-
ditions optimal for the preferential destruction of hematological
malignancies, and potentially other neoplasms.
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